AMENDMENTS TO THE CLAIMS

Claims 1-80 **Canceled**

81. **(Currently Amended)** A GDF-8 analogue comprising a GDF-8 polypeptide that has been modified by means of at least ~~one modification that comprises substituting~~two substitutions of a first amino acid sequence in SEQ ID NO: 11 or 12 with a second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is selected from more than one ~~or more~~ of residues 1-12, 18-41, 43-48, 49-69 or 79-104 in SEQ ID NO: 11 or 12, or that has been modified by inserting at least one first amino acid sequence in SEQ ID NO: 11 or 12 with at least one second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is from ~~at~~ one or more of residues 1-12, 18-30, 42-51, 82-86 and 105-109 in SEQ ID NO: 11 or 12.

82. **(Previously Presented)** An immunogenic composition comprising an immunologically effective amount of a DGF-8 analogue according to claim 81, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle and optionally an adjuvant.

83. **(Previously Presented)** An immunogenic composition according to claim 82, wherein the adjuvant is selected from the group consisting of the adjuvants of claim 73.

84-102 **Canceled**

103. **(Currently Amended)** A GDF-8 analogue comprising a GDF-8 polypeptide that has been modified by means of at least ~~one modification that comprises substituting at least~~two substitutions of a first amino acid sequence in SEQ ID NO: 12 with a second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is selected from one or more of residues 1-12, 18-41, 43-48, 49-69 or 79-104 in SEQ ID NO: 12 or that has been modified by inserting at least one first amino acid sequence in SEQ ID NO: 11 or 12 with at least one second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is from ~~at~~ one or more of residues 1-12,18-30, 42-51, 82-86, and 105-109 in SEQ ID NO:12.

104. **(Previously Presented)** The GDF-8 analogue according to claim 103, wherein the modification is made in residues 18-41 of SEQ ID NO: 12.

105. **(Currently Amended)** A GDF-8 analogue comprising a GDF-8 polypeptide that has been modified by at least one modification selected from the group consisting of
- substituting a first amino acid sequence in SEQ ID NO: 11 or 12 with a second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is from one or more of residues 1-12, 18-41, 43-48, 49-69 or 79-104 in SEQ ID NO: 11 or 12;
- inserting at least one amino acid which comprises a foreign T_H epitope at one or more of residues 1-12, 18-30, 42-51, 82-86 or 105-109 in SEQ ID NO: 11 or 12,
~~- adding an amino acid sequence which comprises a foreign T_H epitope at the N- or C-terminus to SEQ ID NO: 11 or 12;~~
-substituting a first amino acid sequence in SEQ ID NO: 11 or 12 with a second amino acid sequence which comprises a foreign TH epitope, wherein said first amino acid sequence is a loop area or a flexible terminus in the GDF-8 polypeptide comprising SEQ ID NO:11 or 12; and
- inserting at least one amino acid sequence which comprises a foreign T_H epitope into a loop areas or in a flexible terminus in the GDF-8 polypeptide comprising SEQ ID NO: 11 or 12;
wherein the number of amino acid ~~additions, insertions, deletions,~~ and substitutions does not exceed 60.

106. **(Previously Presented)** The method according to claim 105, wherein the foreign T_H epitope is introduced by means of insertion.

107. **Canceled**

108. **(Previously Presented)** The method according to claim 105, wherein the foreign T_H epitope is introduced by means of substitution.

109. **(Previously Presented)** The method according to claim 105, wherein the foreign T_H epitope is promiscuous.

110. **(Previously Presented)** An immunogenic composition comprising an immunologically effective amount of a GDF-8 analogue according to claim 105, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle and optionally an adjuvant.